In a separate study by Chekol et al., [89Zr]Zr-DFO-nimotuzumab effectively differentiated EGFR-positive from EGFR-negative breast cancer xenografts starting at 24 h post-injection, with the greatest distinction observed at 7 days post-injection. Here, EGFR is linked to breast carcinoma.